Where Silence Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Silence Therapeutics (NASDAQ:SLN) has received 6 analyst ratings in the last quarter, with 1 being bullish and 5 somewhat bullish. The average price target is $21.0, compared to the current price of $6.29, implying an upside. The average price target has increased by 5.0% over the past month.
August 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics has received positive analyst ratings, which could lead to an increase in its stock price.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Silence Therapeutics has received predominantly positive ratings, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100